Findings

What do systematic reviews say?

5 questions · 5 findings · 4 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 20%Low 1 · 20%Moderate 3 · 60%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Adults: higher dose/longer course vs lower dose/shorter course · All adverse events
  Different oral corticosteroid regimens for acute asthma 2016 · Cochrane Headline outcomes only
  OR 4.15 [0.94, 18.41]
  1 study · 43 participants
  Very low
Direct match · question page
- Long‐acting muscarinic antagonists (LAMA) add‐on vs long‐acting beta2‐agonists (LABA) add‐on · Adverse events (all)
  Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting… 2015 · Cochrane Headline outcomes only
  OR 1.11 [0.92, 1.35]
  3 studies · 1839 participants
  Moderate
Direct match · question page
- Children: higher dose/longer course vs lower dose/shorter course · All adverse events
  Different oral corticosteroid regimens for acute asthma 2016 · Cochrane Headline outcomes only
  OR 0.67 [0.11, 4.08]
  1 study · 201 participants
  Moderate
Direct match · question page
- Stopping LABA vs continuing use of LABA+ICS · Adverse events (all)
  Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes only
  OR 0.83 [0.66, 1.05]
  5 studies · 1339 participants
  Moderate
Related · question page
- LAMA add‐on vs ICS alone · All‐cause serious adverse events 24 weeks
  Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for… 2015 · Cochrane Headline outcomes only
  OR 0.6 [0.23, 1.57]
  5 studies · 2562 participants
  Low

LAMA add‐on vs long‐acting beta2‐agonists (LABA) add‐on

Adverse events (all) · adults with asthma not well controlled on ICS

Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in adverse events (all) compared with long‐acting beta2‐agonists (LABA) add‐on (moderate certainty).

1 finding from 1 review

Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting… 2015 · Cochrane Headline outcomes only
OR 1.11 [0.92, 1.35]
3 studies · 1839 participants
Moderate

Adults: higher dose/longer course vs lower dose/shorter course

All adverse events · Adults with acute asthma

It is very uncertain whether adults: higher dose/longer course changes all adverse events compared with lower dose/shorter course (very low certainty).

1 finding from 1 review

Different oral corticosteroid regimens for acute asthma 2016 · Cochrane Headline outcomes only
OR 4.15 [0.94, 18.41]
1 study · 43 participants
Very low

Children: higher dose/longer course vs lower dose/shorter course

All adverse events · children with acute asthma

Children: higher dose/longer course showed no clear difference in all adverse events compared with lower dose/shorter course (moderate certainty).

1 finding from 1 review

Different oral corticosteroid regimens for acute asthma 2016 · Cochrane Headline outcomes only
OR 0.67 [0.11, 4.08]
1 study · 201 participants
Moderate

Stopping LABA vs continuing use of LABA+ICS

Adverse events (all) · adults with asthma well controlled on LABA and ICS

Stopping LABA showed no clear difference in adverse events (all) compared with continuing use of LABA+ICS (moderate certainty).

1 finding from 1 review

Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes only
OR 0.83 [0.66, 1.05]
5 studies · 1339 participants
Moderate

LAMA add‐on vs ICS alone

All‐cause serious adverse events 24 weeks · adults with asthma not well controlled on ICS

LAMA add‐on showed no clear difference in all‐cause serious adverse events 24 weeks compared with ICS alone (low certainty).

1 finding from 1 review

Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for… 2015 · Cochrane Headline outcomes only
OR 0.6 [0.23, 1.57]
5 studies · 2562 participants
Low